Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Karuna closes $42mm Series A round to advance KarXT schizophrenia candidate

Executive Summary

CNS-focused Karuna Pharmaceuticals Inc. (muscarinic receptors for psychiatric and cognitive disorders) raised $42mm in a Series A round; $22mm of that amount includes the issuance of shares upon conversion of debt into equity. Investors in the financing included Arch Venture Partners, the Wellcome Trust, Steven Paul, MD (a former Eli Lilly executive and chairman of the Karuna board), parent PureTech Health (which holds a 58.4% ownership), and other undisclosed backers.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies